2361 studies found for:    EGFR
Show Display Options
Rank Status Study
21 Not yet recruiting Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
Condition: Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
Intervention: Drug: Chidamide with EGFR-TKI
22 Not yet recruiting Endostar Plus EGFR-TKI(Epidermal Growth Factor Receptor—Tyrosine-Kinase Inhibitor) as a Treatment of EGFR Mutation-positive NSCLC
Conditions: Advanced Cancer;   Lung Cancer, Nonsmall Cell
Intervention: Drug: EGFR-TK Inhibitor
23 Completed Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas
Condition: Non-small Cell Lung Cancer Metastatic
Intervention: Biological: CTC
24 Recruiting Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc
Condition: Advanced Stage Non Small Cell Lung Cancer
Interventions: Drug: Erlotinib 100mg qd;   Drug: Gefitinib 250mg qd
25 Completed Europe-Japan Diagnostic Study for EGFR Testing
Condition: EGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.
Intervention:
26 Completed Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions
Condition: Advanced Colorectal Cancer
Intervention: Drug: Cetuximab, irinotecan
27 Terminated A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors
Condition: EGFR Positive Solid Tumors
Intervention: Drug: IMGN289
28 Completed Detecting EGFR T790M Mutations From Circulating Tumor Cells
Condition: Non Small Cell Lung Cancer
Intervention: Device: Circulating tumor cell chip
29 Unknown  Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC
Condition: Asymptomatic Brain Metastases of Non Small Cell Lung Cancer
Intervention: Drug: EGFR-TKI
30 Recruiting Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)
Condition: Stage IV EGFR Mutated NSCL With Brain Metastases
Interventions: Drug: Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib;   Radiation: WBRT;   Radiation: HFSRS
31 Recruiting Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC
Condition: Non Small Cell Lung Cancer
Interventions: Drug: EGFR-TKIs;   Radiation: thoracic radiotherapy
32 Completed Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m
Condition: Newly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer
Intervention:
33 Recruiting Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study
Condition: EGFR Mutation Positive Non Small Cell Lung Cancer
Intervention:
34 Recruiting Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA
Conditions: Lung Neoplasms;   EGFR Gene Mutations
Intervention: Drug: Osimertinib
35 Not yet recruiting EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism
Condition: Non-Small-Cell Lung Cancer
Interventions: Drug: EGFR-TKI;   Drug: Chemotherapy(pemetrexed/gemcitabine);   Drug: Chemotherapy(carboplatin)
36 Active, not recruiting Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients
Condition: Metastatic Non-Small-Cell Lung Cancer
Intervention:
37 Recruiting PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLC
Condition: Carcinoma, Non-Small-Cell Lung
Intervention:
38 Recruiting Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC
Conditions: NSCLC;   EGFR Mutation
Intervention: Drug: Erlotinib
39 Recruiting TORC1/2 Inhibitor INK128 and EGFR Inhibitor AZD9291 in Treating Patients With Advanced EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Osimertinib;   Other: Pharmacological Study;   Drug: Sapanisertib
40 Completed Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.